Kyverna Therapeutics, Inc. Common Stock (KYTX NASDAQ) stock market data APIs
$8.2176
-0.1(-1.2%)
as of August 14, 2026
Try our APIs with
free plan!
Kyverna Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Prev. Close
8.2176
Open
8.1204
High
8.3449
Low
7.7638
52 wk Range
3.27-13.67
Market Cap
505 M
Shares Outstanding
61 843 K
EPS
-0.63
Beta
1.937
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kyverna Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyverna Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Kyverna Therapeutics, Inc. Common Stock Fundamental Data
Kyverna Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -157 364 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kyverna Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -0.67
Get Kyverna Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyverna Therapeutics, Inc. Common Stock News
New
Kyverna Therapeutics Sinks 13%: Here’s Why
Quick Read KYTX dropped 12% after JPMorgan trimmed its price target to $29, despite beating Q1 estimates and initiating a rolling BLA for miv-cel targeting a 2027 launch. BEAM slid 8% from a 52-week ...
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middl...
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
Pharmaceutical companies can offer investors huge returns if treatments under development become blockbuster drugs. Choosing between a speculative clinical-stage play and a dominant cash-flow engine r...
Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic ar...
Get Kyverna Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
